(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/183943 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 25/00* (2006.01)
A61K 31/5025 (2006.01)

(21) International Application Number:
PCT/US2023/064967

(22) International Filing Date:
24 March 2023 (24.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

17/704,983	25 March 2022 (25.03.2022)	US
63/420,930	31 October 2022 (31.10.2022)	US
63/443,874	07 February 2023 (07.02.2023)	US

(71) Applicant: **VENTUS THERAPEUTICS U.S., INC.** [US/US]; 100 Beaver Street, Suite 202, Waltham, Massachusetts 02453 (US).

(72) Inventors; and

(71) Applicants: **DORICH, Stéphane** [CA/CA]; 124 avenue Pendennis, Pointe-Claire, Québec H9R 1H6 (CA). **CHEFSON, Amandine** [CA/CA]; 868 rue Jogues, Montreal, Québec H4E 2W8 (CA). **CIBLAT, Stéphane** [CA/CA]; 1260 rue Pauline-Julien, Montreal, Québec H2J 0A2 (CA).


(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES



(I)

(57) Abstract: The present disclosure relates to inhibitors of NLRP3 of Formula (I): (I), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R^1, R^2, R^3, R^4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.

WO 2023/183943 A1